FAPI PET在肺部肿瘤管理中的应用
本文综述FAPI PET/CT在肺癌中的应用,指出FAP在非小细胞肺癌中的表达高于小细胞肺癌亚型;FAPI PET/CT对原发肿瘤和转移灶的检出率与[18F]FDG PET/CT相当或更优,尤其在脑、胸膜和骨病灶中,并可提高淋巴结分期准确性、影响疾病管理。
要点
- FAP在非小细胞肺癌中的表达高于小细胞肺癌亚型。
- FAPI PET/CT对原发肿瘤和转移灶的检出率与[18F]FDG PET/CT相当或更优,尤其在脑、胸膜和骨病灶中。
- FAPI PET/CT可提高淋巴结分期准确性,使被[18F]FDG PET/CT误分类的病例得以手术切除。
核心结论
- FAPI PET/CT是变革性的诊断工具,在精准肺癌诊疗中可补充或可能超越[18F]FDG PET/CT。
研究设计与样本
- 本文为综述,聚焦FAPI PET/CT在肺癌分期、生物标志物评估和临床管理中的作用。
主要发现
- FAP表达与肺癌中癌症相关成纤维细胞驱动的肿瘤发生相关,非小细胞肺癌中的表达高于小细胞肺癌亚型。
- FAPI PET/CT对原发肿瘤和转移灶的检出率与[18F]FDG PET/CT相当或更优,尤其在脑、胸膜和骨病灶中。
- FAPI PET/CT可提高淋巴结分期准确性,使被[18F]FDG PET/CT误分类的病例得以手术切除,从而影响疾病管理。
关键数值与推荐
- 非小细胞肺癌中的FAP表达高于小细胞肺癌亚型。
- FAPI PET/CT对原发肿瘤和转移灶的检出率与[18F]FDG PET/CT相当或更优,尤其在脑、胸膜和骨病灶中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 区分良恶性病变仍存在挑战。
- 评估FAPI的预后意义或其治疗反应监测作用仍存在挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP), selectively expressed on activated fibroblasts in proliferating tissues, is emerging as a promising target in oncology. In lung cancer, the leading cause of cancer-related deaths worldwide, [18F]FDG PET/CT has set the bar high and earned widespread recognition in clinical guidelines for its essential role in staging and follow-up. Yet, FAP-targeted imaging agents like FAPI PET/CT have demonstrated significant potential due to their high tumor specificity, rapid tracer uptake, and low background activity. This review focuses on the role of FAPI PET/CT in lung cancer, highlighting its applications in staging, biomarker evaluation, and clinical management. FAP expression correlates with cancer associated fibroblast-driven tumorigenesis in lung cancer, showing higher expression in nonsmall cell lung cancer (NSCLC) than in small cell lung cancer (SCLC) subtypes. Studies reveal that FAPI PET/CT provides comparable or superior detection rates for primary tumors and metastases compared to [18F]FDG PET/CT, particularly in brain, pleural, and bone lesions. It also enhances accuracy in lymph node staging, influencing disease management by enabling surgical resection in cases misclassified by [18F]FDG PET/CT. Despite these advantages, several challenges remain, such as differentiating benign from malignant lesions, assessing FAPI's prognostic implications or its role in treatment response monitoring. Future directions include exploring FAPI-based theranostics, standardizing radiopharmaceuticals, and conducting well-designed, adequately powered prospective trials. FAPI PET/CT represents a transformative diagnostic tool, complementing or potentially surpassing [18F]FDG PET/CT in precision lung cancer care.
引用
- Deleu AL, Shagera QA, Veldhuijzen van Zanten S, et al. FAPI PET in the Management of Lung Tumors. Semin Nucl Med. 2025. PMID: 40037979. doi:10.1053/j.semnuclmed.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。